Navigation Links
DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
Date:4/10/2013

titute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact

Jeffrey A. Bacha
President & CEO
DelMar Pharmaceuticals
(604) 629-5989

-or-

Booke & Company Investor Relations
admin@bookeandco.com

 


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
2. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
3. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
4. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
5. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
6. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
7. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
8. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
9. Global Pharmacy Automation Market 2012-2016 with McKesson Corp., ScriptPro LLC, Parata Systems LLC Dominating
10. Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite to Achieve e-Pedigree Compliance
11. Zosano Pharma, Inc. Announces Key Strategic Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... DANVERS, Mass. , Aug. 27, 2014 North ... with a prestigious R&D 100 Award for the new OSRAM ... laser and LED-based white light module for microscopy, endoscopy and ... Xenon lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of ...
(Date:8/27/2014)... Aug. 27, 2014 Amgen (NASDAQ: ... Administration (FDA) has granted priority review designation for ivabradine ... is an oral drug that inhibits the I ... node, the body,s cardiac pacemaker. 1 Ivabradine works ... myocardial contractility or ventricular repolarization. 1 Heart failure ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... First U.S. Clinical Data on XIENCE V ... Follow-Up,Results from the ABSORB Bioabsorbable Stent Clinical ... /PRNewswire-FirstCall/ --,Abbott will present data from several ... during a number of late-breaking,clinical trial and ...
... La Jolla,Pharmaceutical Company today announced updated interim antibody,reduction ... (abetimus,sodium), its drug candidate for systemic lupus erythematosus,("lupus" ... that there is a definitive and significant dose ... mg doses of Riquent compared,with placebo (p=0.0001). These ...
Cached Medicine Technology:Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
(Date:8/28/2014)... 28, 2014 The next episode of ... from Tallahassee, Fla. He’s a drama coach who longs ... frame has made achieving that dream impossible. , Featuring ... Weight Loss” airs Tuesday, September 2 (9:00-11:00 p.m., ET/PT) ... wears a big smile on the outside to hide ...
(Date:8/27/2014)... The report provides market analysis of “Military ... Finder, LIDAR, 3D scanner, Laser Weapon, Dazzlers, Laser sights, ... Altimeter) by Domain (Aerospace, Defense and Homeland Security) - ... MarketsandMarkets, and its application in the aerospace and defense ... Systems market is expected to register a CAGR of ...
(Date:8/27/2014)... FL (PRWEB) August 27, 2014 ... money-saving dental plans, has launched in the state ... access to quality, affordable dental care services at ... destination for Tennessee consumers looking to save money ... dental rates as a member of discount fee ...
(Date:8/27/2014)... National Resident Matching Program International ... Medical Education in Europe (AMEE) Conference being held at ... – September 3, 2014. As an exhibitor, NRMPI ... community, share the benefits of its matching services, and ... in countries throughout the world. , “Exhibiting ...
(Date:8/27/2014)... Arrow, OK (PRWEB) August 27, 2014 When ... their guests a comfortable bed to sleep without breaking the ... the market for a new foam mattress set for the ... to sleep on, Bedding Mart has it all during their ... stock up on some of the best mattresses for the ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Rod’s Journey Begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Military Laser Systems Market Worth $2.73 Billion by 2020 - New Report by MarketsandMarkets 4Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 3Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Bedding Mart, Top Mattress Store in Broken Arrow Oklahoma, Announces a Huge Labor Day Sale 2
... accident, skull separating from her spine, has survived to tell ... ,A car crash slammed her into the dashboard. Her ... and other internal organs remained intact. The rare condition is ... no control over her head. ,Surgeons said her ...
... Since it is a very painful process, continuous attempts are ... the patient. ,Now researchers say that LHRH agonists ... the production of a female hormone that encourages some tumours ... often mimicking the action of a naturally occurring substance. ...
... affects to work, sleep and performance of other activities but ... and your concentration. ,This is the finding ... Rashiq at the University of Alberta. ,As a ... Pain Centre in Edmonton, Canada, the researchers studied 24 patients, ...
... a type of kidney malignancy called renal cancer according to ... Women's Hospital in Boston found that women and men who ... about 30 percent less likely to develop renal cell cancer ... drank beer, wine or liquor. ,Jung Eun Lee ...
... addition of folic acid to flour or bread mandatory in order ... ,After lengthy public consultations the Food Standards Agency (FSA) ... next month after it decides whether folic acid should be added ... the FSA's proposals, it will be the first time since the ...
... of Psychiatric and Mental Health Nursing in a recent report, ... health support to the victims of the 2005 Bali ... first explosions in 2002. ,Staff at the Royal ... recipients of vital personal support from mental health nurses. ...
Cached Medicine News:Health News:30-year-old Woman Survives 'internal Decapitation' 2Health News:A Fresh Alternative to Painful Chemotherapy Developed in UK 2Health News:Chronic Pain can Impair Memory and Concentration 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3Health News:Bali Bombings Helped Improve Trauma Care 2Health News:Bali Bombings Helped Improve Trauma Care 3
... Most practitioners consider the HOPE nebulizer the ... have been made to put everything together in ... The result is our #11320 Adult HOPE Kit ... corrugated tubing and pediatric aerosol mask all in ...
... medication nebulizers offer a spill-proof design and ... a 45° angle. All medical nebulizers are ... variety of configurations are available., ,All ... ,Portex® medication nebulizers feature consistently fine ...
... delivery of medication as well as humidification, ... closed dilution, high volume, continuous medication nebulizer ... to patients. Its 200 ml reservoir and ... 8 hours of nebulized medication delivery at ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: